Michael Gladstone

Michael Gladstone is the founder of Q32 Bio Operations, Inc. Current roles include Director at Kailera Therapeutics, Inc. since 2024; Director at DOT Therapeutics-2, Inc.; Independent Director at Third Harmonic Bio, Inc. since 2019; Non-Executive Director & Board Member at Versanis Bio, Inc.; Director at Diagonal Therapeutics, Inc.; Director at Aiolos Bio, Inc.; Partner at Atlas Venture Advisors, Inc. since 2020; Principal at Padlock Therapeutics, Inc.; Partner at Atlas Venture Life Science Advisors LLC since 2020; and Board Member at Pheon Therapeutics Ltd. since 2022.
Former roles include Independent Director at Day One Biopharmaceuticals, Inc.; Operations Director at Spero Therapeutics, Inc.; Director-Business Operations at Surface Oncology, Inc.; Director at Replimune Group, Inc.; Director at AVROBIO, Inc.; Director at IFM Therapeutics LLC; Director at Delinia, Inc.; Director at Indalo Therapeutics, Inc.; Director at Akero Therapeutics, Inc.; Director at Xilio Therapeutics LLC; Senior Associate Consultant at The Lek; and Principal at Beth Israel Deaconess Medical Center, Inc. Education includes an undergraduate degree from Harvard College, conferred in 2009.